Status:
COMPLETED
Ketamine Infusion as Sedative Analgesic in Severe ARDS
Lead Sponsor:
Interfaith Medical Center
Conditions:
Intensive Care Unit Syndrome
Mechanical Ventilation Complication
Eligibility:
All Genders
18-90 years
Brief Summary
To evaluate whether ketamine is a safe sedative-analgesic agent to be used in an intensive care unit (ICU) setting as compared to traditionally used agents such as propofol, opioids, and midazolam
Detailed Description
According to the 2018 Clinical Practice Guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the intensive care uni...
Eligibility Criteria
Inclusion
- moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 with an arterial partial pressure of oxygen divided by the inspired oxygen concentration (P/F) ratio \< 150 with a minimum 5 cm of positive end-expiratory pressure on a mechanical ventilator
Exclusion
- post-cardiac arrest status,
- premorbid diagnosis of dementia,
- dependency on extra-corporeal therapies prior to or during ICU stay
Key Trial Info
Start Date :
February 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 14 2021
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT04818827
Start Date
February 1 2020
End Date
February 14 2021
Last Update
March 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Interfaith Medical Center
New York, New York, United States, 11414